open access

Vol 16, No 3 (2020)
Research paper
Published online: 2020-04-28
Get Citation

The prevalence of depression, anxiety, and stress in patients with breast cancer in Southeast Iran in 2019: a cross-sectional study

Seyed-Mehdi Hashemi, Mohammadreza Hormozi, Abolghasem Allahyari, Ali Arash Anoushirvani, Zahra Ameri, Samaneh Ghasemipour
DOI: 10.5603/OCP.2020.0015
·
Oncol Clin Pract 2020;16(3):104-108.

open access

Vol 16, No 3 (2020)
ORIGINAL ARTICLES
Published online: 2020-04-28

Abstract

Introduction. Today, breast cancer patients suffer from various psychological symptoms that impose irreversible effects on their quality of life. The aim of the present study was to determine the prevalence of depression, anxiety, and stress in patients with breast cancer.

Material and methods. This descriptive study was performed on 190 women with breast cancer from January 1, 2019 to July 30, 2019. Data collection was carried out using a convenience sampling method. The Standard Depression, Anxiety, and Stress Scale (DASS-21) was used to assess depression, anxiety, and stress.

Results. The mean age of the patients was 46.3 years. Results showed the prevalence of depression, anxiety, and stress to be 28.4%, 43.2%, and 14.7%, respectively.

Conclusion. The results indicate that it is vital to measure the level of depression and anxiety in women with
breast cancer, which are two common mental disorders in breast cancer.

Abstract

Introduction. Today, breast cancer patients suffer from various psychological symptoms that impose irreversible effects on their quality of life. The aim of the present study was to determine the prevalence of depression, anxiety, and stress in patients with breast cancer.

Material and methods. This descriptive study was performed on 190 women with breast cancer from January 1, 2019 to July 30, 2019. Data collection was carried out using a convenience sampling method. The Standard Depression, Anxiety, and Stress Scale (DASS-21) was used to assess depression, anxiety, and stress.

Results. The mean age of the patients was 46.3 years. Results showed the prevalence of depression, anxiety, and stress to be 28.4%, 43.2%, and 14.7%, respectively.

Conclusion. The results indicate that it is vital to measure the level of depression and anxiety in women with
breast cancer, which are two common mental disorders in breast cancer.

Get Citation

Keywords

breast cancer; depression; anxiety, stress

About this article
Title

The prevalence of depression, anxiety, and stress in patients with breast cancer in Southeast Iran in 2019: a cross-sectional study

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 3 (2020)

Article type

Research paper

Pages

104-108

Published online

2020-04-28

DOI

10.5603/OCP.2020.0015

Bibliographic record

Oncol Clin Pract 2020;16(3):104-108.

Keywords

breast cancer
depression
anxiety
stress

Authors

Seyed-Mehdi Hashemi
Mohammadreza Hormozi
Abolghasem Allahyari
Ali Arash Anoushirvani
Zahra Ameri
Samaneh Ghasemipour

References (43)
  1. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6): 438–451.
  2. John R, Ross H. The global economic cost of cancer. Atlanta, GA: American Cancer Society and LIVESTRONG. 2010.
  3. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220.
  4. Chang L, Weiner LS, Hartman SJ, et al. Breast cancer treatment and its effects on aging. J Geriatr Oncol. 2019; 10(2): 346–355.
  5. Charalampopoulou M, Kritseli E, Chrousos GP, et al. Efficacy of stress management and psychosocial interventions on body image in breast cancer survivors-A systematic review. Dialogues in Clinical Neuroscience & Mental Health. 2019; 2(4): 237–242.
  6. Shim EJ, Lee JW, Cho J, et al. Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea. Breast Cancer Res Treat. 2020; 179(2): 491–498.
  7. Kugbey N, Oppong Asante K, Meyer-Weitz A. Depression, anxiety and quality of life among women living with breast cancer in Ghana: mediating roles of social support and religiosity. Support Care Cancer. 2019 [Epub ahead of print].
  8. van Oers H. Aspects of Post-Traumatic Stress Disorder symptomatology in patients with breast cancer: a review of prevalence, risk and mediating factors. World Scientific News. 2019; 120(2): 266–74.
  9. Peng Li, Huang W, Zhang W, et al. Psychometric properties of the short form of the fear of cancer recurrence inventory (FCRI) in chinese breast cancer survivors. Front Psychiatry. 2019; 10: 537.
  10. Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 176(3): 519–533.
  11. Peoples AR, Garland SN, Pigeon WR, et al. Cognitive behavioral therapy for insomnia reduces depression in cancer survivors. J Clin Sleep Med. 2019; 15(1): 129–137.
  12. Kim SC, Shaw BR, Shah DV, et al. Interactivity, presence, and targeted patient care: mapping e-Health intervention effects over time for cancer patients with depression. Health Commun. 2019; 34(2): 162–171.
  13. Hashemi SM, Rafiemanesh H, Aghamohammadi T, et al. Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis. Breast Cancer. 2020; 27(2): 166–178.
  14. LeVasseur N, Li H, Cheung W, et al. Effects of high anxiety scores on surgical and overall treatment plan in patients with breast cancer treated with neoadjuvant therapy. Oncologist. 2019 [Epub ahead of print]; 25(3): 212–217.
  15. Tang Y, Fu F, Gao H, et al. Art therapy for anxiety, depression, and fatigue in females with breast cancer: A systematic review. J Psychosoc Oncol. 2019; 37(1): 79–95.
  16. An Y, Fu G, Yuan G. Quality of life in patients with breast cancer: the influence of family caregiver's burden and the mediation of patient's anxiety and depression. J Nerv Ment Dis. 2019; 207(11): 921–926.
  17. Osman A, Wong JL, Bagge CL, et al. The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates. J Clin Psychol. 2012; 68(12): 1322–1338.
  18. Asghari A, Saed F, Dibajnia P. Psychometric properties of the Depression Anxiety Stress Scales-21 (DASS-21) in a non-clinical Iranian sample. Int J Psychol. 2008; 2(2): 82–102.
  19. Jafari P, Nozari F, Ahrari F, et al. Measurement invariance of the Depression Anxiety Stress Scales-21 across medical student genders. Int J Med Educ. 2017; 8: 116–122.
  20. Oei TPS, Sawang S, Goh YW, et al. Using the Depression Anxiety Stress Scale 21 (DASS-21) across cultures. Int J Psychol. 2013; 48(6): 1018–1029.
  21. Tonsing KN. Psychometric properties and validation of Nepali version of the Depression Anxiety Stress Scales (DASS-21). Asian J Psychiatr. 2014; 8: 63–66.
  22. von Elm E, Altman D, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008; 61(4): 344–349.
  23. Montazeri A, Sajadian A, Ebrahimi M, et al. Depression and the use of complementary medicine among breast cancer patients. Support Care Cancer. 2005; 13(5): 339–342.
  24. Taghavi M, Kalafi E, Talei A, et al. Investigating the relation of depression and religious coping and social support in women with breast cancer. Journal of Isfahan Medical School. 2011; 28(115).
  25. Nikbakhsh N, Moudi S, Abbasian S, et al. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014; 5(3): 167–170.
  26. Ramezani T. Degree of depression and the need for counseling among women with breast cancer in Kerman chemotherapeutic centers. 2001.
  27. Mashhadi MA, Shakiba M, Zakeri Z. Evaluation of depression in patients with cancer in South of iran (zahedan). Iran J Cancer Prev. 2013; 6(1): 12–16.
  28. Badana ANS, Marino VR, Templeman ME, et al. Understanding the roles of patient symptoms and subjective appraisals in well-being among breast cancer patients. Support Care Cancer. 2019; 27(11): 4245–4252.
  29. Shayan Z, Shahkolahi Z, Ahmadlo N, et al. Prognostic factors of depression in patients with cancer undergoing chemotherapy and radiotherapy. Health Scope. 2014; 3(4).
  30. Sudarisan SS, Abraham B, George C. Prevalence, correlates of depression, and its impact on quality of life of cancer patients attending a palliative care setting in South India. Psychooncology. 2019; 28(6): 1308–1313.
  31. Adjei Boakye E, Osazuwa-Peters N, Mohammed KA, et al. Prevalence and factors associated with diagnosed depression among hospitalized cancer patients with metastatic disease. Soc Psychiatry Psychiatr Epidemiol. 2020; 55(1): 15–23.
  32. Lee Y. Chien C-Y, fang F-M, lin P-Y. Prevalence and risk factors of depression in patients with head and neck cancer: a literature review. International Journal of Head and Neck Science. 2019; 3(3): 140–51.
  33. Peng YN, Huang ML, Kao CH. Prevalence of Depression and Anxiety in Colorectal Cancer Patients: A Literature Review. Int J Environ Res Public Health. 2019; 16(3).
  34. Mahdavi A, Mosavimoghadam S, Madani Y, et al. Effect of intensive short-term dynamic psychotherapy on emotional expressiveness and defense mechanisms of women with breast cancer. Archives of Breast Cancer. 2019: 35–41.
  35. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychological Medicine. 2010; 40(11): 1797–1810.
  36. Caruso R, Breitbart W. Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions. Epidemiol Psychiatr Sci. 2020; 29: e86.
  37. Larkin DR. Routine depression screenings for advanced cancer patients: reducing disparities, identifying depression, and improving quality of life. J Hosp Palliat Nurs. 2020; 22(1): 12–16.
  38. Grotmol K, Lie H, Loge J, et al. Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients. Palliative and Supportive Care. 2018; 17(2): 143–149.
  39. Serfaty M, King M, Nazareth I, et al. Effectiveness of cognitive–behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial. The British Journal of Psychiatry. 2019; 216(4): 213–221.
  40. Lethborg C, Kissane DW, Schofield P. Meaning and Purpose (MaP) therapy I: Therapeutic processes and themes in advanced cancer. Palliat Support Care. 2019; 17(1): 13–20.
  41. Lueboonthavatchai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai. 2007; 90(10): 2164–2174.
  42. Parada H, Sun X, Tse CK, et al. Lifestyle Patterns and Survival Following Breast Cancer in the Carolina Breast Cancer Study. Epidemiology. 2019; 30(1): 83–92.
  43. Bahri N, Fathi Najafi T, Homaei Shandiz F, et al. The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies. Breast Cancer Res Treat. 2019; 176(1): 53–61.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl